Researchers identify #VCP as a key regulator of CD8+ T cell suppression in #HCC, showing that targeting VCP restores T cell #Antitumor function and synergizes with #AntiPD1 therapy to overcome #Immunosuppression in the #TME. #medsky

#OpenAccess in #STTT: doi.org/10.1038/s413...

LinkedIn This link will take you to a page that’s not on LinkedIn

🔗 Check out the OncoDaily feature here: lnkd.in/eb-VTa67

#Glioblastoma #GBM #BrainCancer #CancerImmunotherapy #Immunotherapy #TME #antiPD1 #PNAS #OncoDaily #ResearchHighlight

Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1 - Nature Reviews Immunology In this Perspective, Honjo and co-workers describe the discovery of PD1 and its journey to become a major target for cancer immunotherapy. It discusses the complex regulatory systems that govern PD1 e...

"Insights from a 30-year journey: function, regulation & therapeutic modulation of PD1"
From 2023: a history of the development of #antiPD1 #immunotherapy by Honjo, Chamoto et al. @natrevimmunol.nature.com
#Immunology #Immunosky
www.nature.com/articles/s41...

Soluble #CD27 differentially predicts resistance to #antiPD1 alone but not with anti-CTLA-4 in #melanoma

By I. Sam, N. Benhamouda, L. Biard, L. Da Meda, K. Desseaux, C. Lebbe, E. Tartour & colleagues @cancerparisnord.bsky.social @hopitalpompidou.bsky.social

➡️ doi.org/10.1038/s443...

If you're not redirected in a few seconds, click here

Un article de gran interés en descobrir una peça #metabòlica que impacte en la eficàcia de la #immunoteràpia i té sinergia amb la teràpia #antiPD1 en el tractament dels #tumors #sòlids.

Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1 - Nature Reviews Immunology In this Perspective, Honjo and co-workers describe the discovery of PD1 and its journey to become a major target for cancer immunotherapy. It discusses the complex regulatory systems that govern PD1 e...

"Insights from a 30-year journey: function, regulation & therapeutic modulation of PD1"
Fm @natrevimmunol.bsky.social 2023: a history of the development of #antiPD1 #immunotherapy by Honjo, Chamoto et al.
#Immunology #Immunosky
www.nature.com/articles/s41...